“Risk-Based” Enforcement Approach to Homeopathic Products Will Be Taken By Federal Regulators

FDA will only step in with enforcement when homeopathic products constitute a potential health threat, according to new guidance issued this week

The U.S. Food and Drug Administration (FDA) issued final guidance this week which indicates the agency intends to take a “risk-based” approach to enforcing regulations regarding homeopathic drug products sold to Americans.

The updated position was published in the Federal Register (PDF) on December 6, after a draft guidance was issued in October 2019. The agency also withdrew a Compliance Policy Guide, which limited the FDA’s enforcement on homeopathic products.

The guidance focuses on prioritizing categories of homeopathic products that are considered higher risk for some consumers. These are products that may pose side effects for those with weakened immune systems, infants and children, the elderly, and pregnant women.

The guidance also focuses on ophthalmic and injectable products. The routes of administration for injectable drug products bypass some of the body’s natural defenses and can pose a greater risk in some cases.

Homeopathic Drug Risks

Homeopathy is an alternative medicine practice developed in the late 1700s. It is based on the principle that a substance which causes symptoms in a healthy person can be used in diluted form to treat symptoms and illnesses.

Drug products sold as homeopathic remedies are made from a wide range of substances, including ingredients derived from plants, healthy and diseased animals, human sources, minerals, and chemicals. Some are known to be safe, but others have been found to be poisonous or toxic, depending on the dose or quantity.

The products are often marketed as natural alternatives to prescription and non-prescription drugs, which are widely available in the U.S., but require an FDA approval process to confirm they are safe and effective.

Did You Know?

AT&T Data Breach Impacts Millions of Customers

More than 73 million customers of AT&T may have had their names, addresses, phone numbers, Social Security numbers and other information released on the dark web due to a massive AT&T data breach. Lawsuits are being pursued to obtain financial compensation.

Learn More

In recent years, the FDA has issued warnings to about serious risks identified with certain homeopathic products. The warnings highlighted products containing toxic substances, such as belladonna, and products made under poor manufacturing standards, which led to contamination and recalls.

Currently, there are no FDA-approved products labeled as homeopathic. The agency said it cannot ensure the safety of homeopathic products, as they do not meet the FDA’s standards for effectiveness and quality.

The FDA anticipates many homeopathic products will fall outside the categories of regulation for drug products intended to be under this enforcement but highlights efforts to enforce regulation and safety on these products.

1 Comments

  • StanDecember 15, 2022 at 7:58 pm

    Its too bad the FDA doesnt take a similar precautionary approach to the "injectable" Covid vaxs.

Share Your Comments

I authorize the above comments be posted on this page*

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

This field is for validation purposes and should be left unchanged.

More Top Stories

BioZorb Lawsuit Alleges Breast Tissue Marker Failed, Requiring Surgical Removal
BioZorb Lawsuit Alleges Breast Tissue Marker Failed, Requiring Surgical Removal (Posted yesterday)

A BioZorb lawsuit has been filed by several breast cancer survivors after the BioZorb implants moved out of place and failed to dissolve int he body, requiring surgical removal.

Fairness Hearing For Philips CPAP Recall Medical Monitoring Settlement Set for October
Fairness Hearing For Philips CPAP Recall Medical Monitoring Settlement Set for October (Posted yesterday)

A U.S. District Court judge has scheduled a fairness hearing for October in order to determine whether final approval should be granted to a $25 million Philips CPAP recall settlement agreement, which would pay former users $25 million to pay for future medical monitoring needs.